Your SlideShare is downloading. ×
Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2014
Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2014
Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2014
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2014

153

Published on

This report provides comprehensive information on the current therapeutic developmental pipeline of Lixte Biotechnology Holdings, Inc.s, complete with comparative analysis at various stages, …

This report provides comprehensive information on the current therapeutic developmental pipeline of Lixte Biotechnology Holdings, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Get Detail Report With TOC @ http://www.researchmoz.us/lixte-biotechnology-holdings-inc-product-pipeline-review-2014-report.html

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
153
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2014 Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2014 Summary Global Markets Directs, Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2014, provides an overview of the Lixte Biotechnology Holdings, Inc.s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Lixte Biotechnology Holdings, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Lixte Biotechnology Holdings, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Lixte Biotechnology Holdings, Inc.s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Lixte Biotechnology Holdings, Inc.s pipeline products Reasons to buy - Evaluate Lixte Biotechnology Holdings, Inc.s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Lixte Biotechnology Holdings, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Lixte Biotechnology Holdings, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Lixte Biotechnology Holdings, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lixte Biotechnology Holdings, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Lixte Biotechnology Holdings, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues Table Of Contents table Of Contents 2 list Of Tables 4 list Of Figures 4 lixte Biotechnology Holdings, Inc. Snapshot 5 lixte Biotechnology Holdings, Inc. Overview 5 key Information 5 key Facts 5 lixte Biotechnology Holdings, Inc. - Research And Development Overview 6 key Therapeutic Areas 6 lixte Biotechnology Holdings, Inc. - Pipeline Review 9 pipeline Products By Stage Of Development 9 pipeline Products - Monotherapy 10 lixte Biotechnology Holdings, Inc. - Pipeline Products Glance 11 Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2014
  • 2. lixte Biotechnology Holdings, Inc. - Clinical Stage Pipeline Products 11 phase I Products/combination Treatment Modalities 11 lixte Biotechnology Holdings, Inc. - Early Stage Pipeline Products 12 preclinical Products/combination Treatment Modalities 12 lixte Biotechnology Holdings, Inc. - Drug Profiles 13 lb-100 13 product Description 13 mechanism Of Action 13 r&d Progress 13 lb-201 15 product Description 15 mechanism Of Action 15 r&d Progress 15 lb-205 16 product Description 16 mechanism Of Action 16 r&d Progress 16 lb-300 Series 17 product Description 17 mechanism Of Action 17 r&d Progress 17 lb-400 Series 18 product Description 18 mechanism Of Action 18 r&d Progress 18 lixte Biotechnology Holdings, Inc. - Pipeline Analysis 19 lixte Biotechnology Holdings, Inc. - Pipeline Products By Target 19 lixte Biotechnology Holdings, Inc. - Pipeline Products By Route Of Administration 20 lixte Biotechnology Holdings, Inc. - Pipeline Products By Molecule Type 21 lixte Biotechnology Holdings, Inc. - Pipeline Products By Mechanism Of Action 22 lixte Biotechnology Holdings, Inc. - Recent Pipeline Updates 23 lixte Biotechnology Holdings, Inc. - Dormant Projects 25 lixte Biotechnology Holdings, Inc. - Company Statement 26 lixte Biotechnology Holdings, Inc. - Locations And Subsidiaries 30 head Office 30 appendix 31 methodology 31 coverage 31 secondary Research 31 primary Research 31 expert Panel Validation 31 contact Us 32 disclaimer 32 list Of Tables lixte Biotechnology Holdings, Inc., Key Information 5 lixte Biotechnology Holdings, Inc., Key Facts 5 lixte Biotechnology Holdings, Inc. - Pipeline By Indication, 2014 8 lixte Biotechnology Holdings, Inc. - Pipeline By Stage Of Development, 2014 9 lixte Biotechnology Holdings, Inc. - Monotherapy Products In Pipeline, 2014 10 lixte Biotechnology Holdings, Inc. - Phase I, 2014 11 lixte Biotechnology Holdings, Inc. - Preclinical, 2014 12 lixte Biotechnology Holdings, Inc. - Pipeline By Target, 2014 19 lixte Biotechnology Holdings, Inc. - Pipeline By Route Of Administration, 2014 20 lixte Biotechnology Holdings, Inc. - Pipeline By Molecule Type, 2014 21 lixte Biotechnology Holdings, Inc. - Pipeline Products By Mechanism Of Action, 2014 22 lixte Biotechnology Holdings, Inc. - Recent Pipeline Updates, 2014 23 lixte Biotechnology Holdings, Inc. - Dormant Developmental Projects,2014 25 list Of Figures lixte Biotechnology Holdings, Inc. - Pipeline By Top 10 Indication, 2014 7 lixte Biotechnology Holdings, Inc. - Pipeline By Stage Of Development, 2014 9 lixte Biotechnology Holdings, Inc. - Monotherapy Products In Pipeline, 2014 10 lixte Biotechnology Holdings, Inc. - Pipeline By Top 10 Target, 2014 19 lixte Biotechnology Holdings, Inc. - Pipeline By Top 10 Route Of Administration, 2014 20 lixte Biotechnology Holdings, Inc. - Pipeline By Top 10 Molecule Type, 2014 21 lixte Biotechnology Holdings, Inc. - Pipeline Products By Top 10 Mechanism Of Action, 2014 22 Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2014
  • 3. ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Lixte Biotechnology Holdings, Inc. - Product Pipeline Review - 2014

×